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Abstract 
N-Sulfonyl-N'-benzimidazol-2-yl acetamidines have been designed as CK1 inhibitors. Binding modes in the ATP 
pocket of CK1 were determined by molecular modeling. The synthetic approach involves sequential acylation 
of 2-aminobenzimidazoles followed by reaction of amides with Lawesson’s reagent and iminosulfonylation of 
thioamides with sulfonyl azides. The iminosulfonylation was carried out in boiling ethanol with an equivalent 
ratio of azides and thioamides. The synthesized compounds were tested for their ability to inhibit CK1 
isoforms in vitro and to inhibit the growth of tumor cell lines. Among the synthesized compounds, two 
products showed inhibitory abilities towards CK1δ and CK1ε. 
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Introduction 
 
The benzimidazole nucleus is a constituent of numerous therapeutic agents, and its derivatives exhibit various 
types of bioactivity including anticancer, antimicrobial, antiviral, anti-inflammatory, antiparasitic, antioxidant, 
proton pump inhibiting, antihypertensive, etc.1 Modification by an amino group, nitrogen atoms of imidazole 
ring, and CH bonds of benzene ring also results in formation of biologically active compounds.1 Richter et al. 
have found that N-aminoacylated benzimidazoles inhibit сasein kinase 1 (CK1) and exhibit nanomolar 
anticancer activity.2 On the other hand, N-sulfonyl amidines have been introduced as osteoclast differentiation 
inhibitors, anti-resorptive agents3, and dopamine transport inhibitors.4 It is therefore a worthwhile challenge 
to develop previously unknown hybrid molecules containing both a benzimidazole and an N-sulfonylamidine 
group, with the aim of finding new biologically active compounds. 
 
Results and Discussion 
 
Herein, we report a novel synthetic approach to new benzimidazole derivatives bearing N-sulfonyl 
acetamidine groups, and preliminary data on their inhibition of casein kinases. The design of the structures 
planned for the CK1 inhibition activity testing, along with the plan to synthesize the desired compounds, are 
shown in Scheme 1. A series of 2-aminobenzimidazoles bearing various substituents including a dioxole ring, 
the use of acetic anhydride, acetyl chloride and trifluoroacetic anhydride as acylating reagents, and the use of 
mesyl azide and various other sulfonyl azides demonstrated the variety of the structures of the planned 
compounds. Acylation (A), thionation (T) and iminosulfonylation (IS) were steps applied for the retrosynthesis 
of target molecules. 
 
 
 
Scheme 1.  Retrosynthetic design of N-benzimidazol-2-yl-N'-sulfonyl acetamidines. 
 
Reactions corresponding to transformation A are widely used in the synthesis of various acylamido 
derivatives of benzimidazoles.5-8 To introduce R4 of a small size acetic anhydride and trifluoroacetic anhydride 
were selected. Reactions corresponding to step T involve Lawesson’s reagent. They have been applied for the 
synthesis of 2-thiocarbamoyl benzimidazoles in which R4 is only aryl.9 The general method for the synthesis of 
N-sulfonylamidines involves alkylation followed by treatment of alkyl thioimidates with amines10 and then 
with sulfonyl chlorides (step IS). However, the low yield of the target compounds forced us to rule out this 
method from consideration. Recently a N-sulfonylamidines synthesis based on a Cu catalyzed three 
component reaction11 was  developed and applied to the synthesis of benzimidazol-2-yl-N-sulfonylamidines 
bearing R4 aryl and long alkyl groups12 but cannot be used for the synthesis of amidines of acetic acid (R4 = Me) 
designed for testing of biological activity. We turned our attention to a one-step synthesis of sulfonylamidines 
involving the reaction of enamines and thiomides with sulfonyl azides.4,13-18 This approach has successfully 
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been applied to the synthesis of N-sulfonyl amidines from cyclic thioamides13 and active methylene 
thioamides,4,14 and therefore it was selected as the method of choice for the synthesis of the target 
compounds. 
The starting amides 1a-h were prepared in high yields in the reaction of commercially available 2-
aminobenzimidazoles with acetyl chloride (or acetic anhydride) and trifluoroacetic anhydride for the synthesis 
of acetamido (1a-f) and trifluoroacetamido (1g,h) benzimidazoles, respectively. The novel thioamides 2a-h 
were prepared by treatment of amides 1a-h in boiling 1,4-dioxane with Lawesson’s reagent, which was found 
earlier to be efficient for the synthesis of various types of thioamide.19-21 
To prepare the targeted sulfonyl amidines 4 we have studied reactions of thioamides 2a-h with a variety 
of sulfonyl azides 3a-g bearing methyl, aryl, or heteroaryl moieties in various reaction conditions. First we tried 
to avoid any solvent. The corresponding protocol was successfully used earlier to prepare sulfonylamidines 
from methylene active thioamides.4,14 However we were not able to isolate any new compounds apart from 
the initial reagents and some sort of tar. The darkening of the reaction mass took place while no nitrogen 
evolution being a characteristic feature of azidation of thioamide4,14 was fixed. The adding a few drops of DMF 
did not improve the situation. Thioamides 2c,d did not react with sulfonyl azides 1a,b in water, though this 
solvent was successfully used to prepare other types of amidine.14,16 The reason may involve the very low 
solubility of thioamides 2 in water. Luckily, the reaction of (benzimidazol-2-yl)ethanethioamides 2a-h with 
azides 3a-g occurred when the mixture of thioamides 2 and sulfonyl azides 3 in equivalent ratio (for the 
reaction of thioamide 2f with azide 3c 5.0 equiv. of the azide was used) was heated in boiling ethanol for 2-10 
h. We have also found that thioamides of trifluoroacetic acid 2g,h did not react with sulfonyl azides under any 
conditions. (Scheme 2; Figure 1) 
The structures of all new compounds were reliably confirmed by the combination of 1H and 13C NMR 
spectroscopy including 2D HMBC and HSQC experiments, as well as mass spectrometry. Thus, 1H NMR spectra 
of amides 1d,f, thioamides 2a-h, and amidines 4a-o display methyl group singlets and benzene ring protons at 
2.16-2.71 and 7.04-8.10 ppm, respectively. The characteristic signals in the 13C NMR spectra at 201.3–203.7 
ppm of the thioamides 2a-h, corresponding to carbons of the thioamide group, were observed. Signals of 
carbons of amidine groups of compounds 4a-o appear at 163.3-167.5 ppm, i.e. close to signals for methylene 
active N-sulfonyl amidines.4,14 
 
 
Scheme 2.  Synthesis of (benzimidazol-2-yl)ethanethioamides 2a-h and (benzimidazol-2-yl)acetamidines 4a-o. 
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Figure 1.  Structures of N-sulfonylacetamidines 4a-o prepared according to Scheme 2. 
 
Additional proof for the proposed structures of compounds 4a-o was achieved by X-ray analysis of a single 
crystal of 4o which was successfully obtained by crystallization from ethyl acetate (Figure 2). The compound 
crystallized in the centrosymmetric space group of the triclinic system. The molecule has a Г-like configuration. 
The bonds lengths and interatomic angles in the molecules do not show any significant deviations from 
standard. The amidine moiety is fixed in the plane of the heterocycle in the limits 0.1 Å by intramolecular H-
bonds, the C-atom of CF2-group deviated from the least-squares plane of the heterocycle by 0.2 Å. The 
fluorophenyl substituent deviated from the plane of the heterocycle, the dihedral angle between the planes of 
the rings is 72о and the interatomic angle N(2)–S(1)–C(8) is 102.55(15)о. In the crystal the molecules form 
dimeric intermolecular H-bonds NH...N with participation of the amidine NH-group and N-atom of the 
imidazole, and NH...O H-bonds between imidazole and O-atom of the SO2-group. 
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Figure 2.  Compound 4o according to XRD data in the thermal ellipsoids of the 50% probability level. 
 
A plausible mechanism of the formation of amidines 4 is depicted in Scheme 3. We propose the formation 
of intermediate thiatriazolines A via 1,3-dipolar cycloaddition with inverse electron demand of the azido group 
of sulfonyl azides to the C=S bond of thioamides 2. The fact that thioamides 2g,h bearing electron withdrawing 
CF3 group does not react with sulfonyl azides is in accord with this interpretation. The elimination of 
dinitrogen and sulfur from thiatriazoline A finalizes the formation of amidines 4. 
 
 
 
Scheme 3.  Plausible mechanism of formation of N-sulfonyl amidines 4. 
 
Molecular Modeling 
Energetically minimized ligand conformations were docked (see Experimental part) into the active site of CK1 
and CK1, respectively. Binding poses were determined and subsequently ranked based on their calculated 
binding affinities. While we did not obtain a plausible binding mode for CK1, the top ranked binding poses 
and the corresponding 2D ligand interaction diagrams for CK1 are shown in Figure 3. Consistent with the 
binding mode of benzimidazole inhibitors in CK1 determined by X-ray crystallography in our study a highly 
similar situation could be obtained for 2c. Herein, the 2-amino-benzimidazole core is involved in key H-bonds 
towards the hinge motif Leu85. The CF3 motif occupies the hydrophic pocket surrounded by Ile148/23, Met80, 
Tyr56, and Pro66. On the other site, the thioacetate moiety is oriented towards the hydrophobic region which 
opens to the solvent exposed area. Thus, based on the binding mode of hit fragment 2c, a structure based 
optimization approach towards more potent CK1 inhibitors will be developed. 
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Figure 3. Modeled binding modes of 2c in the ATP-binding pocket of CK1δ (pdb 4TWC). Key amino acid 
residues and ligand-active site interactions are shown (left). Right: corresponding 2D ligand interaction 
diagram. 
 
Inhibitory effects of selected compounds on the kinase activity of CK1 isoforms 
Selected compounds were initially screened for their activity against different CK1 isoforms against a 
concentration of 10 µM ATP. Under these conditions, the synthesized compounds did not show activities on 
CK1α and CK1γ3. Modest activities were found for 2c and 4l which slightly inhibit CK1δ and CK1ε respectively.  
Hit compound 2c showed an IC50 value of approximately 7 µM for CK1δ and 4l an IC50 of 4.86 µM for CK1ε 
(Figure 4). Although these values are significantly weaker than IC50 values of known highly potent CK1-specific 
inhibitors,22 our results suggest that our scaffolds might be improved for further development of potent CK1 
isoform kinase inhibitors. 
 
 
 
Figure 4.  IC50 curves of relevant compounds against CK1δ and CK1ε. Curve A: 2c; curve B: 4l. 
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Conclusions 
 
We have demonstrated a simple, efficient and convenient three-step synthesis of N-benzimidazol-2-yl-N'-
sulfonyl amidines of acetic acid from commercially available reagents. Fifteen compounds were successfully 
obtained and tested for inhibition of casein kinases. Among the synthesized compounds, two products showed 
inhibitory abilities towards CK1δ and CK1ε. The search for more active compounds using the developed 
synthetic approach is in progress in our laboratories. 
 
 
Experimental Section 
 
General. 1H and 13C NMR spectra (including 2D HMBS and HSQC) were recorded with Bruker Avance II 
spectrometer in DMSO-d6 at 50 
oC (400 and 100 MHz, respectively) using Me4Si as an internal standard. Mass 
spectra were recorded with Shimadzu GCMS-QP2010 Ultra instrument in electron ionization (EI) mode. 
Electron energy - 70eV. IR spectra were obtained with Bruker Alpha (NPVO, ZnSe) IR-Fur spectrometer. 
Microanalyses were performed with PerkinElmer Series II CHNS/O 2400 elemental analyzer. Melting points 
were determined using a Stuart SMP 3 apparatus. The progress of the reactions and the purity of the 
compounds were monitored by TLC on TLC Silica gel 60 F245 aluminum sheets (Merck KGaA) in EtOAc-PE 
system. 
 
X-Ray analysis. The single-crystal X-ray diffraction data for 4o were collected with a "Xcalibur 3" 
diffractometer (Oxford Diffraction) with CCD detector applying the standard procedure (CuKα-irradiation (λ = 
1.54184 Å), graphite monochromator, ω-scans with step 1о at T = 295(2) K). Empirical absorption correction 
was applied. The structure was solved by direct method with SHELX97 and was refined by full-matrix least 
squares on F2 using SHELX97.23 
Synthesis. The amides 1a-с,e,g were synthesized by known procedures.5-7,24 
Ethyl 2-acetamido-1H-benzimidazole-5-carboxylate (1d). A solution of ethyl 2-amino-1H-benzimidazole-5-
carboxylate (1.20 g, 5.85 mmol) in excess of acetic anhydride (5 mL) was refluxed for 1 h. Water (30 mL) was 
added to the cooled reaction mixture and the resulting suspension was stirred for 30 min. The formed 
precipitate was filtered off, washed with water, dried and crystallized from ethyl acetate. Colorless powder, 
yield 1.02 g (70%), mp 293-295 oС. 1H NMR (400 MHz, DMSO-d6) δ 1.33 (t, J 8.0 Hz, 3H, CH3CH2O), 2.18 (s, 3Н, 
СН3), 4.31 (q, J 8.0 Hz, 2H, CH3CH2O), 7.50 (d, J 8.0 Hz, 1H, CHarom.), 7.76 (d, J 8.0 Hz, 1H, CHarom.), 8.10 (s, 1H, 
CHarom.), 11. 58 (br. s, 1H, NH), 12. 19 (br. s, 1H, NH). 
13С (100 MHz, DMSO-d6) δ 14.1 (CH3CH2O), 23.0 (CH3), 
60.0 (CH3CH2O), 114.0 (C-7), 115.2 (C-4), 122.3 (C-6), 122.5 (C-5), 134.9 (C-3a), 140.4 (C-7a), 148.6 (C-2), 168.2 
(C-5'), 169.7 (C-2'). MS m/z EI (70 eV), (I,%): 247 [M+] (50), 205 (100), 177 (30), 160 (80), 132 (30), 105 (29). IR 
(ATR, ZnSe): νmax (cm
-1) 1470, 1509, 1585, 1620, 1684, 1724, 3210, 3303. Anal. Calcd for C12H13N3O3 (247.25): 
C, 58.29; H, 5.30; N, 17.00. Found: C, 58.58; H, 5.49; N, 16.85. 
N-(2,2-Difluoro-5H-[1,3]dioxolo[4,5-e]benzimidazol-6-yl)acetamide (1f). To 2,2-difluoro-5H-[1,3]dioxolo[4,5-
e]benzimidazol-6-amine hydrobromide (1.46 g, 4.96 mmol, 1.0 equiv.) in anhydrous DCM (6 mL) DIPEA (0.77 g, 
0.98 mL, 5.95 mmol, 1.2 equiv.) was added. The resulting solution was stirred at room temperature for 10 min 
and then cooled to 10 oС. Then acetyl chloride (0.467 g, 0.42 mL, 5.95 mmol, 1.2 equiv.) was added to the 
solution. The resulting suspension was stirred for 5 h. The formed precipitate was filtered off. The filtrate was 
evaporated to dryness and water was added to the residue. An additional portion of crude acetamide 1f was 
filtered off. The combined precipitates were transferred to a glass beaker and saturated aq. NaHCO3 (25 mL) 
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was added. The resulting suspension was stirred for 20 min and the precipitate was filtered off, washed with 
water and dried. The crude product was crystallized from ethanol. Colorless powder, yield 0.98 g (77%), mp > 
300 oС. 1H NMR (400 MHz, DMSO-d6) δ 2.16 (s, 3Н, СН3), 7.40 (s, 2Н, Нarom.), 11.53 (br. s, 1Н, NH), 12.12 (br. s, 
1Н, NH). 13С (100 MHz, DMSO-d6) δ 23.0 (С-10), 94.1 (С-7), 98.3 (С-4), 128.0 (С-3а), 131.2 (t, J 250.0 Hz, С-8), 
135.9 (С-7а), 138.3 (2C, С-5, С-6), 146.9 (С-2), 169.5 (С=О). MS EI (70 eV), m/z (I,%): 255 [M]+ (38), 213 (100), 
147 (25), 119 (40), 43 (42). IR (ATR, ZnSe): νmax (cm
-1) 1129, 1213, 1245, 1463, 1604, 1650, 1683, 2943, 3331. 
Anal. Calcd for C10H7F2N3O3 (255.18): C, 47.07; H, 2.77; N, 16.47. Found: C, 47.38; H, 2.52; N, 16.60%. 
2,2,2-Trifluoro-N-(5-methyl-1H-benzimidazol-2-yl)acetamide (1h). Trifluoroacetic anhydride (6.0 mmol, 1.26 
g, 0.77 mL, 2.0 equiv.) was added to a solution of 5-methyl-1H-benzimidazol-2-amine (3.0 mmol, 0.44 g, 1.0 
equiv.) in anhydrous 1,4-dioxane (15 mL) at 10 oC. The reaction mixture was stirred at room temperature for 4 
h. After reaction completion, the mixture was concentrated to dryness under vacuum and water (20 mL) was 
added to the solid residue. The resulting mixture was stirred for 20 min. The precipitate was filtered off, 
washed with water, ethanol, dried at 60 oC and used in the next stage without further purification. Colorless 
precipitate, mp 275-279 oС, yield 80% (0.58 g). 1H NMR (400 MHz, DMSO-d6) δ 2.38 (s, 3Н, СН3), 7.08 (d, J 8.0 
Hz, 1Н, СНarom.), 7.25 (s, 1Н, СНarom.), 7.33 (d, J 8.0 Hz, 1Н, СНarom.), 12.83 (br. s, 2Н, NH). 
13С NMR (100 MHz, 
DMSO-d6) δ 21.0 (CH3), 111.7 (C-7), 111.8 (C-4), 117.3 (q, J 286.3 Hz, СF3), 124.5 (C-6), 126.8 (C-7a), 129.0 (C-
3a), 133.0 (C-5), 152.2 (C-2), 163.1 (q, J 33.6 Hz, C=O). MS m/z EI (70 eV), (I,%): 243 [M+] (52), 174 (100), 146 
(20). IR (ATR, ZnSe): νmax (cm
-1) 1131, 1195, 1573, 1587, 1620, 1636. Anal. Calcd for C10H8F3N3O (243.19): C, 
49.39; H, 3.32; N, 17.28. Found: C, 49.75; H, 3.62; N, 17.50%. 
General procedure for the synthesis of (benzimidazol-2-yl)ethanethioamides 2a-f. A mixture of the 
corresponding amide 1 (3.20 mmol, 1.0 equiv.) and Lawesson’s reagent (1.76 mmol, 0.55 equiv.) was refluxed 
in anhydrous 1,4-dioxane (20 mL) for 6 h. After completion, the reaction mixture was concentrated under 
vacuum to dryness. The crude product was purified by silica gel column chromatography (EtOAc/PE) to afford 
the corresponding thioamide 2. 
N-(1H-Benzimidazol-2-yl)ethanethioamide (2a). Yellow powder, mp 203-205 oС, yield 51% (0.31 g), eluent: 
EtOAc/PE (1:2). 1H NMR (400 MHz, DMSO-d6) δ 2.67 (s, 3H, CH3), 7.20-7.22 (m, 2H, CHarom.), 7.55-7.58 (m, 2H, 
CHarom.), 12.92 (br. s, 2H, NH2). 
13С (100 MHz, DMSO-d6) δ 35.9 (СН3), 113.9 (2C, C-4, C-7), 122.2 (2C, C-5, C-6), 
133.4 (2C, C-3a, C-7a), 148.6 (C-2), 203.7 (C=S). MS m/z EI (70 eV), (I, %): 191 [M]+ (47), 176 (20), 150 (30), 133 
(100), 105 (25), 59 (45). IR (ATR, ZnSe): νmax (cm
-1) 1258, 1360, 1441, 1527, 1583, 1630, 1690, 2829, 2930, 
3331. Anal. Calcd for C9H9N3S (191.25): C, 56.52; H, 4.74; N, 21.97. Found: C, 56.74; H, 4.57; N, 21.83 %. 
N-(5-Methyl-1H-benzimidazol-2-yl)ethanethioamide (2b). Light yellow powder, mp 201-203 oС, yield 64% 
(0.42 g), eluent EtOAc/PE (1:4). 1H NMR (400 MHz, DMSO-d6) δ 2.39 (s, 3H, CH3), 2.64 (s, 3H, CH3), 7.03 (d, J 8.0 
Hz, 1H, CHarom.), 7.35 (s, 1Н, СНarom.), 7.44 (d, J 8.0 Hz, 1H, CHarom.), 12.96 (br. s, 2H, NH2). 
13С (100 MHz, DMSO-
d6) δ 21.2 (C-8), 36.3 (C-10), 113.7 (2C, C-4, C-7), 131.0 (C-7a), 131.8 (C-5), 133.1 (C-3a), 148.9 (C-2), 203.6 (C-
9). MS EI (70 eV), m/z (I,%): 205 [M]+ (72), 190 (42), 164 (46), 146 (100), 77 (29), 59 (57). IR (ATR, ZnSe): νmax 
(cm-1) 1303, 1326, 1350, 1436, 1478, 1581, 1600, 1635. Anal. Calcd for C10H11N3S (205.28): C, 58.51; H, 5.40; N, 
20.47. Found: C, 58.32; H, 5.68; N, 20.27%. 
N-(5-(Trifluoromethyl)-1H-benzimidazol-2-yl)ethanethioamide (2c). Yellow powder, mp 225-227 oС, yield 40% 
(0.33 g), eluent EtOAc/PE (1:7). 1H NMR (400 MHz, DMSO-d6) δ 2.73 (s, 3H, CH3), 7.50 (d, J 8.0 Hz, 1H, CHarom.), 
7.76 (d, J 8.0 Hz, 1H, CHarom.), 7.94 (br. s, 1H, CHarom.), 13.10 (br. s, 2H, NH2). 
13С NMR(100 MHz, DMSO-d6) δ 
35.1 (CH3), 112.1 (C-4), 115.1 (C-7), 118.5 (d, J 3.0 Hz, C-6), 122.2 (q, J 32.0 Hz, C-5), 124.8 (q, J 270.0 Hz, C-11), 
134.7 (C-3a), 137.1 (C-7a), 149.3 (C-2), 202.7 (C=S). MS EI (70 eV), m/z (I,%): 259 [M]+ (63), 218 (22), 59 (100). 
IR (ATR, ZnSe): νmax (cm
-1) 1102, 1329, 1528, 1606, 1640, 2824, 3184. Anal. Calcd for C10H8F3N3S (259.25): C, 
46.33; H, 3.11; N, 16.21. Found: C, 46.50; H, 2.89; N, 16.05%. 
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Ethyl 2-(ethanethioamido)-1H-benzimidazole-5-carboxylate (2d). Yellow powder, mp 198-200 oС, yield 70% 
(0.59 g), eluent EtOAc/PE (1:2). 1H NMR (400 MHz, DMSO-d6) δ 1.40 (t, J 8.0 Hz, 3H, CH3CH2O), 2.71 (s, 3H, 
CH3), 4.34 (q, J 8.0 Hz, 2H, CH3CH2O), 7.58-7.60 (m, 1H, Harom.), 7.81-7.84 (m, 1H, Harom.), 8.17-8.20 (m, 1H, 
Harom.), 13.08 (br. s, 2H, NH2). 
13С (100 MHz, DMSO-d6) δ 14.2 (C-10), 35.4 (C-12), 60.3 (C-9), 114.5 (C-7), 116.2 
(C-4), 123.3 (C-6), 123.9 (C-5), 133.2 (C-3a), 139.1 (C-7a), 149.6 (C-2), 166.1 (C-11), 203.3 (C=O). MS EI (70 eV), 
m/z (I, %): 263 [M+] (100), 248 (36), 222 (46), 205 (47), 160 (68), 59 (81). IR (ATR, ZnSe): νmax (cm
-1) 1254, 1361, 
1518, 1576, 1597, 1637, 1694, 2931, 3079, 3205. Anal. Calcd for C12H13N3O2S (263.31): C, 54.74; H, 4.98; N, 
15.96. Found: C, 55.03; H, 5.13; N, 15.85%. 
N-(1-Methyl-1H-benzimidazol-2-yl)ethanethioamide (2e). Beige powder, mp 119-122 oС, yield 57% (0.38 g), 
eluent EtOAc/PE (1:4). 1H NMR (400 MHz, DMSO-d6) δ 2.62 (s, 3H, CH3), 3.68 (s, 3H, CH3), 7.31-7.35 (m, 2Н, 
Нarom.), 7.58 (d, J 8.0 Hz, 1H, CHarom.), 7.70 (d, J 8.0 Hz, 1H, CHarom.), 13.51 (br. s, 1H, NH). 
13С (100 MHz, DMSO-
d6) δ 28.7 (C-10), 38.4 (C-9), 110.0 (C-7), 113.9 (C-4), 123.1 (C-5), 123.3 (C-6), 129.4 (C-3a), 130.4 (C-7a), 150.9 
(C-2), 208.8 (C-8). MS EI (70 eV), m/z (I,%): 205 [M]+ (70), 190 (100), 172 (25), 164 (30), 132 (45), 77 (28), 59 
(26). IR (ATR, ZnSe): νmax (cm
-1) 1395, 1542, 1614, 2934. Anal. Calcd for C10H11N3S (205.28): C, 58.51; H, 5.40; N, 
20.47. Found: C, 58.83; H, 5.58; N, 20.56%. 
N-(2,2-Difluoro-5H-[1,3]dioxolo[4,5-e]benzimidazol-6-yl)ethanethioamide (2f). Light yellow powder, mp 152-
154 oС, yield 51% (0.44 g), eluent EtOAc/PE (1:3). 1H NMR (400 MHz, DMSO-d6) δ 2.69 (s, 3H, CH3), 7.55 (s, 2H, 
СНarom.), 12.92 (br. s, 2Н, NH). 
13С (100 MHz, DMSO-d6) δ 34.9 (СН3), 96.8 (2C, C-4, C-7), 130.9 (2C, C-3a, C-7a), 
131.2 (t, J 253.0 Hz, С-8), 139.1 (2С, С-5, С-6), 147.5 (С-2), 201.3 (С=S). MS EI (70 eV), m/z (I,%): 271 [M]+ (82), 
230 (54), 213 (83), 147 (24), 119 (55), 59 (100). IR (ATR, ZnSe): νmax (cm
-1) 1140, 1246, 1460, 1610, 1647, 1692, 
2938, 3327. Anal. Calcd for C10H7F2N3O2S (271.24): C, 44.28; H, 2.60; N, 15.49. Found: C, 44.11; H, 2.85; N, 
15.65%. 
N-(1H-Benzimidazol-2-yl)-2,2,2-trifluoroethanethioamide (2g). Bright yellow powder, mp 183-187 oС, yield 
66% (0.52 g), eluent EtOAc/PE (1:8). 1H NMR (400 MHz, DMSO-d6) δ 7.37-7.41 (m, 2Н, Нarom.), 7.63-7.66 (m, 2Н, 
Нarom.), 13.64 (br. s, 2Н, NH). 
13С (100 MHz, DMSO-d6) δ 112.7 (2C, C-4, C-7), 118.4 (q, J 278.0 Hz, C-9), 124.3 
(2C, C-5, C-6), 128.4 (2C, C-3a, C-7a), 151.6 (C-2), 187.5 (q, J 34.0 Hz, C-8). MS EI (70 eV), m/z (I,%): 245 [M]+ 
(49), 176 (100), 149 (28), 118 (24), 88 (16). IR (ATR, ZnSe): νmax (cm
-1) 973, 1131, 1267, 1430, 1553, 1614, 3022, 
3351. Anal. Calcd for C9H6F3N3S (245.22): C, 44.08; H, 2.47; N, 17.14. Found: C, 43.90; H, 2.60; N, 17.25 %. 
2,2,2-Trifluoro-N-(5-methyl-1H-benzimidazol-2-yl)ethanethioamide (2h). Bright yellow powder, mp 226-239 
oС, yield 57% (0.47 g), eluent EtOAc/PE (1:4→1:2). 1H NMR (400 MHz, DMSO-d6) δ 2.44 (s, 3H, CH3), 7.22 (d, J 
8.0 Hz, 1H, СНarom.), 7.43 (s, 1Н, СНarom.), 7.54 (d, J 8.0 Hz, 1H, СНarom.), 13.62 (br. s, 2Н, NH). MS EI (70 eV), m/z 
(I, %): 259 [M]+ (40), 190 (100), 95 (30), 77 (20). IR (ATR, ZnSe): νmax (cm
-1) 1117, 1182, 1270, 1452, 1563, 1610, 
2923, 3096. Anal. Calc for C10H8F3N3S (259.25): C, 46.33; H, 3.11; N, 16.21. Found: C, 46.68; H, 3.39; N, 16.04%. 
General procedure for the synthesis of (E)-N-(1H-benzimidazol-2-yl)-N'-sulfonylacetimidamides 4a-o.A 
solution of thioamide 2 (1.3 mmol, 1.0 equiv.) and sulfonyl azide 3 (1.3 mmol, 1.0 equiv.) in anhydrous EtOH (8 
mL) was refluxed for 2-10 h. After completion, the reaction mixture was concentrated under vacuum to 
dryness, and the residue was purified by flash chromatography over silica gel (60−120) using EtOAc/PE 
mixtures or crystallized from EtOH. 
(E)-N-(1H-Benzimidazol-2-yl)-N'-(methylsulfonyl)acetimidamide (4a). Reaction time 5 h. Colorless powder, 
mp 285-287 oС (from EtOH), yield 82% (0.27 g). 1H NMR (400 MHz, DMSO-d6) δ 2.53 (s, 3H, CH3), 3.22 (s, 3H, 
SO2CH3), 7.15-7.17 (m, 2H, CHarom.), 7.48-7.50 (m, 2H, CHarom.), 11.83 (br. s, 2H, NH). 
13C NMR (100 MHz, 
DMSO-d6): δ 20.9 (C9), 42.8 (C-10), 113.9 (2C, C-4, C-9), 121.8 (2C, C-5, C-6), 134.9 (2C, C-3a, C-7a), 146.5 (C-2), 
165.0 (C-8). MS EI (70 eV), m/z (I, %): 252 [M+] (25), 132 (100), 105 (42). IR (ATR, ZnSe): νmax (cm
-1) 1061, 1285, 
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1455, 1514, 1565, 1618, 2815, 3360. Anal. Calcd for C10H12N4O2S (252.29): C, 47.61; H, 4.79; N, 22.21. Found: 
C, 47.83; H, 4.95; N, 22.09%. 
(E)-N-(1H-Benzimidazol-2-yl)-N'-tosylacetimidamide (4b). Reaction time 5 h. Colorless powder, mp 243-245 oС 
(from EtOH), yield 66% (0.28 g). 1H NMR (400 MHz, DMSO-d6): δ 2.37 (s, 3H, 4-CH3C6H4), 2.41 (s, 3H, CH3), 
7.19-7.21 (m, 2H, CHarom.), 7.35 (d, J 8.0 Hz, 2H, CHarom.), 7.51-7.53 (m, 2H, CHarom.), 7.86 (d, J 8.0 Hz, 2H, 
CHarom.), 12.03 (br. s, 2H, NH). 
13C NMR (100 MHz, DMSO-d6): δ 20.9 (C-10), 21.4 (C-9), 113.8 (2C, C-4, C-9), 
122.3 (2C, C-5, C-6), 126.3 (2C-o), 129.3 (2C-m), 133.8 (2C, C-3a, C-7a), 140.2 (C-i), 142.2 (C-p), 147.1 (C-2), 
167.5 (C-8). MS EI (70 eV), m/z (I, %): 328 [M+] (20), 223 (38), 155 (22), 132 (100), 105 (38), 91 (83). IR (ATR, 
ZnSe): νmax (cm
-1) 1093, 1143, 1271, 1454, 1517, 1645, 2897, 3032, 3329. Anal. Calcd for C16H16N4O2S (328.39): 
C, 58.52; H, 4.91; N, 17.06. Found: C, 58.32; H, 5.10; N, 17.14%. 
(E)-N'-[(4-Fluorophenyl)sulfonyl]-N-(5-methyl-1H-benzimidazol-2-yl)acetimidamide (4c). Reaction time 2 h. 
Colorless powder, mp 254-257 oС (from EtOH), yield 67% (0.26 g). 1H NMR (400 MHz, DMSO-d6): δ 2.40 (s, 6H, 
2CH3), 7.03 (d, J 8.0 Hz, 1H, CHarom.), 7.29 (s, 1H, CHarom.), 7.37-7.39 (m, 3H, CHarom.), 8.00-8.04 (m, 2H, CHarom.), 
12.02 (br. s, 2H, NH). 13C NMR (100 MHz, DMSO-d6): δ 21.1 (C-8), 22.1 (C-10), 113.2 (2C, C-4, C-7), 115.9 (d, J 
22.5 Hz, C-m), 123.8 (C-6), 129.2 (d, J 9.2 Hz, C-o), 130.8 (C-7a), 131.9 (C-5), 132.9 (C-3a), 139.9 (d, J 29.0, C-i), 
147.7 (C-2), 163.8 (d, J 248.6 Hz, C-p), 168.3 (C-9). MS EI (70 eV), m/z (I, %): 346 [M+] (18), 159 (18), 146 (100), 
95 (50). IR (ATR, ZnSe): νmax (cm
-1) 1025, 1089, 1148, 1236, 1281, 1345, 1472, 1542, 2886, 3037, 3324. Anal. 
Calcd for C16H15FN4O2S (346.38): C, 55.48; H, 4.37; N, 16.18. Found: C, 55.78; H, 4.04; N, 16.07%. 
(E)-N'-Tosyl-N-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]acetimidamide (4d). Reaction time 3 h. Colorless 
powder, mp 213-216 oС (from EtOH), yield 67% (0.40 g). 1H NMR (400 MHz, DMSO-d6): δ 2.37 (s, 3H, 
4-CH3C6H4), 2.47 (s, 3H, CH3), 7.38 (d, J 8.0 Hz, 2H, CHarom.), 7.49 (t, J 8.0 Hz, 1H, CHarom.), 7.71 (d, J 8.0 Hz, 1H, 
CHarom.), 7.78-7.94 (m, 3H, CHarom.), 12.22 (br. s, 2H, 2NH). 
13C NMR (100 MHz, DMSO-d6): δ 20.2 (C-10), 20.9 (C-
17), 112.1 (C-4), 115.2 (C-7), 118.6 (C-6), 122.3 (q, J 31.0 Hz, C-5), 125.1 (q, J 270.0 Hz, CF3), 126.4 (C-16), 126.5 
(C-12), 129.5 (2C, C-13, C-15), 135.3 (C-3a), 138.1 (C-7a), 139.4 (C-11), 142.7 (C-14), 147.7 (C-2), 166.0 (C-9). 
MS EI (70 eV), m/z (I,%): 396 [M+] (16), 291 (40), 200 (20), 155 (36), 91 (100). IR (ATR, ZnSe): νmax (cm
-1) 1032, 
1092, 1110, 1150, 1275, 1333, 1526, 1632, 1650, 2920, 3017, 3300. Anal. Calcd for C17H15F3N4O2S (396.39): C, 
51.51; H, 3.81; N, 14.13. Found: C, 51.80; H, 3.98; N, 14.04%. 
(E)-N'-[(4-Fluorophenyl)sulfonyl]-N-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]acetimidamide (4e). Reaction 
time 5 h. Colorless powder, mp 255-258 oС (fashed with EtOH), yield 96% (0.51 g). 1H NMR (400 MHz, DMSO-
d6): δ 2.52 (s, 3H, CH3), 7.40 (t, J 8.0 Hz, 2H, CHarom.), 7.48 (d, J 8.0 Hz, 1H, CHarom.), 7.70 (d, J 8.0 Hz, 1H, CHarom.), 
7.89 (s, 1H, CHarom.), 8.05-8.08 (m, 2H, CHarom.), 12.08 (br. s, 2H, 2NH). 
13C NMR (100 MHz, DMSO-d6): δ 20.4 (C-
10), 112.0 (C-4), 115.5 (C-7), 116.1 (d, J 22.6 Hz, C-m), 118.6 (C-6), 122.6 (q, J 31.4 Hz, C-5), 125.0 (q, J 269.9 Hz, 
C-8), 129.4 (d, J 9.3 Hz, C-o), 136.0 (C-3a), 138.4 (C-7a), 138.9 (C-11), 147.8 (C-2), 163.1 (d, J 49.2 Hz, C-p), 
163.4 (C-9). MS EI (70 eV), m/z (I, %): 400 [M+] (19), 295 (36), 200 (44), 173 (16), 159 (53), 95 (100). IR (ATR, 
ZnSe): νmax (cm
-1) 1029, 1087, 1144, 1274, 1331, 1484, 1525, 1630, 1649, 2863, 3013, 3311. Anal. Calcd for 
C16H12F4N4O2S (400.35): C, 48.00; H, 3.02; N, 13.99. Found: C, 47.82; H, 3.25; N, 13.83%. 
Ethyl (E)-2-[N'-(methylsulfonyl)acetimidamido]-1H-benzimidazole-5-carboxylate (4f). Reaction time 7 h. 
Colorless powder, mp 276-279 oС (for purification the crude product was refluxed in ethanol (5 mL) for 5 min 
and filtered off), yield 72% (0.30 g). 1H NMR (400 MHz, DMSO-d6): δ 1.34 (t, J 8.0 Hz, 3H, CH3CH2O), 2.50, (s, 
3H, CH3), 3.25 (s, 3H, CH3SO2), 4.33 (qv, J 8.0 Hz, 2H, CH3CH2O), 7.57 (d, J 8.0 Hz, 2H, Harom.), 7.82 (d, J 8.0 
Hz,1H, Harom.), 8.18 (s, 1H, Harom.), 11.94 (br. s, 2H, 2NH). 
13C NMR (100 MHz, DMSO-d6): δ 14.1 (C-7'), 20.2 (C-
3'), 42.7 (C-4'), 60.2 (C-6'), 114.5 (C-7), 115.3 (C-4), 122.9 (-C6), 123.2 (C-5), 134.9 (C-3a), 140.0 (C-7a), 147.9 
(C-2), 164.3 (C-2'), 166.0 (C=O). MS EI (70 eV), m/z (I,%): 324 (M+, 58), 283 (18), 245 (16), 204 (100), 176 (24), 
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160 (30), 131 (31), 104 (23), 79 (37). IR (ATR, ZnSe): νmax (cm
-1) 1132, 1232, 1254, 1286, 1521, 1556, 1698, 
2960, 3243. Anal. Calc for C19H20N4O4S (324.36): C, 48.14; H, 4.97; N, 17.27. Found: C, 47.90; H, 4.83; N, 17.40%. 
Ethyl (E)-2-(N'-tosylacetimidamido)-1H-benzimidazole-5-carboxylate (4g). Reaction time 4 h. Colorless 
powder, mp 224-227 oС (from EtOH), yield 70% (0.36 g). 1H NMR (400 MHz, DMSO-d6): δ 1.34 (t, J 8.0 Hz, 3H, 
CH3CH2O), 2.37, (s, 3H, CH3), 2.48 (s, 3H, 4-CH3C6H4), 4.33 (q, J 8.0 Hz, 2H, CH3CH2O), 7.38 (d, J 8.0 Hz, 2H, 
Harom), 7.58 (d, J 8.0 Hz, 1H, Harom.), 7.82 (d, J 8.0 Hz, 1H, Harom.), 7.88 (d, J 8.0 Hz, 2H, Harom.), 8.18 (s, 1H, Harom.), 
12.04 (br. s, 2H, 2NH). 13C NMR (100 MHz, DMSO-d6): δ 14.0 (C-7'), 20.3 (C-3'), 20.7 (C-4'), 60.2 (C-6'), 114.2 (C-
7), 115.6 (C-4), 123.1 (C-5), 123.4 (C-6), 126.3 (2C-o), 129.2 (2C-m), 134.6 (C-3a), 139.4 (C-7a), 139.6 (2C-i), 
142.3 (C-p), 147.8 (C-2), 165.9 (C=O), 166.2 (C-2'). MS EI (70 eV), m/z (I,%): 400 [M+] (18), 295 (54), 204 (43), 
155 (36), 91 (100). IR (ATR, ZnSe): νmax (cm
-1) 1154, 1307, 1521, 1701, 2984, 3280. Anal. Calcd for C19H20N4O4S 
(400.45): C, 56.99; H, 5.03; N, 13.99. Found: C, 57.29; H, 5.09; N, 13.75%. 
Ethyl (E)-2-{N'-[(4-methoxyphenyl)sulfonyl]acetimidamido}-1H-benzimidazole-5-carboxylate (4h). Reaction 
time 10 h. Colorless powder, mp 240-244 oС (from EtOH), yield 69% (0.37 g). 1H NMR (400 MHz, DMSO-d6): δ 
1.35 (t, J 8.0 Hz, 3H, CH3CH2O), 2.48, (s, 3H, CH3), 3.83 (s, 3H, 4-CH3OC6H4), 4.33 (q, J 8.0 Hz, 2H, CH3CH2O), 7.09 
(d, J 8.0 Hz, 2H, Harom.), 7.58 (d, J 8.0 Hz, 1H, Harom.), 7.82 (d, J 8.0 Hz, 1H, Harom.), 7.94 (d, J 8.0 Hz, 2H, Harom.), 
8.18 (s, 1H, Harom.), 12.04 (br. s, 2H, 2NH). 
13C NMR (100 MHz, DMSO-d6): δ 14.0 (C-7'), 20.1 (C-3'), 55.4 (C-4'), 
60.2 (C-6'), 114.0 (2C-m), 114.2 (C-7), 115.2 (C-4), 123.0 (C-6), 123.4 (C-5), 128.4 (2C-o), 134.2 (2C-i), 135.2 (C-
3a), 139.9 (C-7a), 147.9 (C-2), 162.0 (C-i), 165.8 (C-2'), 166.0 (C=O). MS EI (70 eV), m/z (I,%): 416 [M]+ (13), 311 
(100), 204 (35), 171 (59), 107 (62), 77 (59). IR (ATR, ZnSe): νmax (cm
-1) 1158, 1315, 1529, 1700, 2989, 3283. 
Anal. Calcd for C19H20N4O4S (416.45): C, 54.80; H, 4.84; N, 13.45. Found: C, 55.14; H, 5.05; N, 13.26%. 
Ethyl (E)-2-{N'-[(4-fluorophenyl)sulfonyl]acetimidamido}-1H-benzimidazole-5-carboxylate (4i). Reaction time 
2 h. Colorless crystals, mp 259-262 oС (from EtOH), yield 73% (0.38 g). 1H NMR (400 MHz, DMSO-d6): δ 1.33 (t, 
J 8.0 Hz, 3H, CH3CH2O), 2.50, (s, 3H, CH3), 4.32 (qv, J 8.0 Hz, 2H, CH3CH2O), 7.42 (t, J 8.0 Hz, 2H, Harom.), 7.59 (d, 
J 8.0 Hz, 1H, Harom.), 7.83 (dd, J 4.0 Hz, J 8.0 Hz, 1H, Harom.), 8.08-8.11 (m, 2H, Harom.), 8.20 (s, 1H, Harom.), 12.21 
(br. s, 2H, 2NH). 13C NMR (100 MHz, DMSO-d6): δ 14.2 (C-7'), 20.7 (C-3'), 60.5 (C-6'), 114.5 (C-7), 115.7 (C-4), 
116.1 (d, J 22.0 Hz, C-m), 123.3 (C-5), 123.5 (C-6), 129.6 (d, J 9.0 Hz, C-o), 134.5 (C-3a), 138.9 (d, J 3.0 Hz, C-i), 
139.4 (C-7a), 147.9 (C-2), 164.06 (d, J 249.0 Hz, C-p), 166.1 (C=O), 166.7 (C-2'). MS EI (70 eV), m/z (I,%): 404 
[M+] (27), 299 (46), 204 (100), 159 (68), 95 (75). IR (ATR, ZnSe): νmax (cm
-1) 1153, 1309, 1521, 1701, 2997, 3297. 
Anal. Calcd for C18H17FN4O4S (404.42): C, 53.46; H, 4.24; N, 13.85. Found: C, 53.62; H, 3.97; N, 13.98%. 
Ethyl (E)-2-(N'-{[2-(methoxycarbonyl)thien-3-yl]sulfonyl}acetimidamido)-1H-benzimidazole-5-carboxylate (4j). 
Reaction time 6 h. Colorless crystals, mp 234-236 oС (from EtOH), yield 68% (0.40 g). 1H NMR (400 MHz, 
DMSO-d6): δ 1.34 (t, J 8.0 Hz, 3H, CH3CH2O), 2.58, (s, 3H, CH3), 3.87 (s, 3H, CH3OCO), 4.32 (q, J 8.0 Hz, 2H, 
CH3CH2O), 7.57 (d, J 8.0 Hz, 1H, Harom.), 7.62 (d, J 8.0 Hz, 1H, Harom.), 7.83 (d, J 8.0 Hz, 1H, Harom.), 7.96 (d, J 8.0 
Hz, 2H, Harom.), 8.13 (s, 1H, Harom.), 12.32 (br. s, 2H, 2NH). 
13C NMR (100 MHz, DMSO-d6): δ 14.0 (C-7'), 20.9 (C-
3'), 52.8 (C-8’), 60.3 (C-6'), 113.9 (C-7), 115.1 (C-4), 123.3 (C-6), 123.6 (C-5), 129.6 (C-12), 131.2 (C-11), 131.3 
(C-13), 133.9 (C-3a), 138.6 (C-7a), 145.5 (C-10), 148.3 (C-2), 160.4 (C-9'), 165.8 (C-5'), 166.3 (C-2'). MS EI (70 
eV), m/z (I,%): 450 [M+] (11), 345 (100), 313 (82), 285 (85), 268 (47), 240 (39), 205 (49), 134 (30), 64 (35). IR 
(ATR, ZnSe): νmax (cm
-1) 1142, 1248, 1310, 1519, 1538, 1706, 2915, 3233. Anal. Calcd for C18H18N4O6S2 (450.48): 
C, 47.99; H, 4.03; N, 12.44. Found: C, 48.20; H, 4.25; N, 12.55%. 
Ethyl (E)-2-{N'-[(3,1,2-benzothiadiazol-4-yl)sulfonyl]acetimidamido}-1H-benzimidazole-5-carboxylate (4k). 
Reaction time 5 h. Colorless crystals, mp 185-187 oС (from EtOH), yield 71% (0.41 g). 1H NMR (400 MHz, 
DMSO-d6): δ 1.34 (t, J 8.0 Hz, 3H, CH3CH2O), 2.71, (s, 3H, CH3), 4.32 (qv, J 8.0 Hz, 2H, CH3CH2O), 7.53 (d, J 8.0 
Hz, 1H, Harom.), 7.80 (d, J 8.0 Hz, 1H, Harom.), 7.88-7.92 (m, 1H, Harom.), 8.05 (s, 1H, Harom.), 8.36-8.39 (m, 2H, 
Harom.), 12.14 (br. s, 2H, 2NH). 
13C NMR (100 MHz, DMSO-d6): δ 14.0 (C-7'), 21.1 (C-3'), 60.2 (C-6'), 113.9 (C-7), 
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115.4 (C-4), 123.2 (C-6), 123.6 (C-5), 125.9 (C-o), 128.6 (C-m), 129.4 (C-p), 133.5 (C-i), 134.4 (C-3a), 138.7 (C-
7a), 148.0 (C-2), 148.9 (C-4'), 155.1 (C-8'), 165.8 (C=O), 166.5 (C-2'). MS EI (70 eV), m/z (I,%): 444 [M+] (18), 339 
(100), 204 (34), 176 (20), 135 (60). IR (ATR, ZnSe): νmax (cm
-1) 1138, 1259, 1318, 1528, 1530, 1703, 2925, 3230. 
Anal. Calcd for C18H16N6O4S2 (444.48): C, 48.64; H, 3.63; N, 18.91. Found: C, 48.97; H, 3.45; N, 18.97%. 
Ethyl (E)-2-{N'-[(3,1,2-benzoxadiazol-4-yl)sulfonyl]acetimidamido}-1H-benzimidazole-5-carboxylate (4l). 
Reaction time 4 h. Colorless powder, mp 215-218 oС, yield 73% (0.41 g). 1H NMR (400 MHz, DMSO-d6): δ 1.34 
(t, J 8.0 Hz, 3H, CH3CH2O), 2.68, (s, 3H, CH3), 4.33 (qv, J 8.0 Hz, 2H, CH3CH2O), 7.51 (d, J 4.0 Hz, 1H, Harom.), 7.76-
7.80 (m, 1H, Harom.), 7.83 (d, J 4.0 Hz, 1H, Harom.), 8.06 (s, 1H, Harom.), 8.22 (d, J 8.0 Hz, 1H, Harom.), 8.34 (d, J 8.0 
Hz, 1H, Harom.), 12.24 (br. s, 2H, 2NH). 
13C NMR (100 MHz, DMSO-d6): δ 14.0 (C-7'), 21.8 (C-3'), 60.3 (C-6'), 113.6 
(C-7), 115.0 (C-4), 120.7 (C-o), 123.4 (C-6), 123.9 (C-5), 130.4 (C-i), 131.5 (C-m), 132.3 (C-p), 133.6 (C-3a), 137.9 
(C-7a), 144.6 (C-4'), 148.2 (C-2), 149.5 (C-8'), 165.7 (C=O), 167.4 (C-2'). MS EI (70 eV), m/z (I,%): 428 [M+] (10), 
323 (100), 278 (20), 206 (33), 178 (20), 64 (29). IR (ATR, ZnSe): νmax (cm
-1) 1035, 1139, 1283, 1316, 1429, 1516, 
1556, 1624, 1708, 2813, 3074, 3327. Anal. Calcd for C18H16N6O5S (428.42): C, 50.46; H, 3.76; N, 19.62. Found: 
C, 50.30; H, 3.57; N, 19.82%. 
(E)-N-(1-Methyl-1H-benzimidazol-2-yl)-N'-tosylacetimidamide (4m). Reaction time 4 h. Colorless powder, mp 
206-210 oС (from EtOH), yield 66% (0.29 g). 1H NMR (400 MHz, DMSO-d6): δ 2.37 (s, 3H, CH3), 3.60 (s, 3H, 
N‒CH3), 7.29-7.35 (m, 4H, CHarom.), 7.53 (d, J 8.0 Hz, 1H, CHarom.), 7.61 (d, J 8.0 Hz, 1H, CHarom.), 7.78 (d, J 8.0 Hz, 
1H, CHarom.), 12.30 (br. s, 1H, NH). 
13C NMR (100 MHz, DMSO-d6): δ 20.9 (C-17), 28.8 (C-8), 113.6 (C-4), 123.2 
(3C, C-3a, C-5, C-6), 126.3 (2C, C-m), 129.2 (2C, C-o), 130.7 (C-7a), 141.0 (C-i), 141.7 (C-p), 148.7 (C-2), 166.1 (C-
9). MS EI (70 eV), m/z (I,%): 342 [M]+ (20), 237 (38), 146 (100), 119 (43), 91 (68). IR (ATR, ZnSe): νmax (cm
-1) 
1004, 1079, 1139, 1270, 1329, 1364, 1399, 1553, 3254. Anal. Calcd for C17H18N4O2S (342.42): C, 59.63; H, 5.30; 
N, 16.36. Found: C, 59.87; H, 5.44; N, 16.23%. 
(E)-N'-((4-Fluorophenyl)sulfonyl)-N-(1-methyl-1H-benzimidazol-2-yl)acetimidamide (4n). Reaction time 4 h. 
Colorless powder, mp 209-211 oС (from EtOH), yield 73% (0.33 g). 1H NMR (400 MHz, DMSO-d6): δ 2.35 (s, 3H, 
CH3), 2.61 (s, 3H, NCH3), 7.28-7.37 (m, 4H, CHarom.), 7.54 (d, J 8.0 Hz, 1H, CHarom.), 7.60 (d, J 8.0 Hz, 1H, CHarom.), 
7.94-7.98 (m, 2H, CHarom.), 12.28 (br. s, 1H, NH). 
13C NMR (100 MHz, DMSO-d6): δ 24.0 (C-10), 28.8 (C-8), 110.3 
(C-7), 113.3 (C-4), 115.6 (C-3a), 115.8 (d, J 21.0 Hz, C-m), 123.3 (2C, C-5, C-6), 129.2 (d, J 9.0 Hz, C-o), 130.5 (C-
7a), 140.3 (d, J 3.0 Hz, C-i), 148.8 (C-2), 163.6 (d, J 248.0 Hz, C-p), 170.9 (C-9). MS EI (70 eV): m/z (I, %): 346 
[M+] (20), 241 (19), 146 (100), 119 (45), 95 (53). IR (ATR, ZnSe): νmax (cm
-1) 1000, 1080, 1139 1228, 1272, 1327, 
1466, 1555, 3251. Anal. Calcd for C16H15FN4O2S (346.38): C, 55.48; H, 4.37; N, 16.18. Found: C, 55.63; H, 4.06; 
N, 16.30%. 
(E)-N-(2,2-Difluoro-5H-[1,3]dioxolo[4,5-e]benzimidazol-6-yl)-N'-[(4-fluorophenyl)sulfonyl]acetimidamide 
(4o). Reaction time 9 h (6.6 mmol (5.0 equiv) of azide 3c were used), light yellow crystals (column, eluent 
EtOAc/PE (3:1)), mp 131-134 oС, yield 70% (0.36 g). 1H NMR (400 MHz, DMSO-d6): δ 2.49, (s, 3H, CH3), 7.37-
7.42 (m, 2H, Harom.), 7.52 (s, 2H, Harom.), 8.02-8.05 (m, 2H, Harom.), 11.92 (br. s, 2H, 2NH). 
13C NMR (100 MHz, 
DMSO-d6): δ 20.0 (C-3'), 96.6 (2C, C-4, C-7), 115.9 (d, J 22.0 Hz, C-m), 129.2 (d, J 9.5 Hz, C-o), 130.9 (2C, C-3a, C-
7a), 131.0 (t, J 250.0 Hz, C-8), 138.8 (d, J 3.0 Hz, C-i), 138.9 (2C, C-5, C-6), 145.5 (C-2), 163.9 (d, J 250.0 Hz, C-p), 
165.6 (C-2'). MS EI (70 eV), m/z (I,%): 412 [M+] (26), 212 (100), 159 (47), 118 (20), 95 (77). IR (ATR, ZnSe): νmax 
(cm-1) 1143, 1234, 1463, 1550, 2898, 3004, 3107, 3277. Anal. Calcd for C16H11F3N4O4S (412.34): C, 46.61; H, 
2.69; N, 13.59. Found: C, 46.53; H, 2.88; N, 13.70%. 
Crystal Data for 4o. Crystal is triclinic, space group P-1, a = 6.823(7), b = 10.989(17), c = 11.360(9) Å, α = 
76.93(10)o, β = 80.77(8)o, γ = 87.12(10)o, V = 818.9(16) Å3, Z = 2, μ(CuKα) = 2.398 mm
-1. On the angles 4.04 < θ < 
67.75o 16712 reflections were collected, 2913 independent reflection (Rint = 0.0515), completeness for θ = 
67.75o 98.1%. Final R-factors of the refinement: R1 = 0.0411, wR2 = 0.1016 [I>2σ(I)]; R1 = 0.0553, wR2 = 0.1048 
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(all data), GooF = 1.002. Maximum and minimum electron density: 0.221 and -0.373 Åē-3. 
Single crystal data for compound 4o (CCDC 1552962) have been deposited in the Cambridge Crystallographic 
Data Center and can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html (or from 
the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Molecular modeling 
Molecular modeling was performed on a DELL Precision T5500 eight core workstation. For visualization 
Maestro, version 10.4, 2014 (Schrödinger LLC, New York, NY, USA) was used.25 Protein structures were 
prepared prior to docking by Schrödinger Protein Preparation Wizard synchronizing the following modules: 
Epik,26 Impact, and Prime.27 Water molecules beyond 5 Å from hetero atoms have been deleted. H-bond 
optimization was performed in a standard sampling, the Root-mean-square deviation for atomic positions 
cutoff of heavy atoms in subsequent protein minimization was set to 0.3 Å. By using this workflow, for CK1δ, 
we generated a model based on the high-resolution structure PDB 4TWC,28 and for CK1 based on PDB 4HNI.29 
Ligands were prepared by MacroModel30 to generate energetically minimized structures. Ionization and 
tautomeric states were processed by LigPrep utilizing Hammet and Taft methodology-based Epik. Additionally, 
Epik state penalties were implemented. Receptor grid were generated by Glide SP settings.29 Energetically 
minimized ligand conformations were docked into the active site of the protein, respectively. Binding poses 
were determined and subsequently ranked based on their calculated binding affinities. 
Biological testing. Materials and methods 
In vitro kinase assays. In vitro kinase assays were performed with different CK1 isoforms and selected 
compounds at an ATP concentration of 10 µM and using DMSO controls as described previously.32,33 Bovine 
GST-CK1α (FP296)34 human GST-CK1γ (FP1054)35 human GST-CK1δ TV1 (FP1417),36 and recombinant human 
GST-CK1ε (FP455)37 were used as sources of enzyme. Phosphorylated proteins were separated by SDS-PAGE 
and stained with Coomassie. α-casein served as a substrate for all kinase assay reactions. Phosphate 
incorporation was detected by autoradiography of dried gels. The phosphorylated protein bands were cut out 
and quantified by Cherenkov counting. Dose-response analyses were carried out using GraphPad Prism 6 
(GraphPad Software, Inc., La Jolla CA, USA) statistical software. In vitro kinase assays were performed in the 
presence or absence of the selected compounds. CK1α, CK1γ3, CK1δ, and CK1ε were used as sources of 
enzyme and α-casein as substrate. All compounds were used at a concentration of 10 µM. Kinase reactions 
were separated by SDS-PAGE and quantification of phosphate incorporation was performed by Cherenkov 
counting. Results are shown as normalized bar graphs using DMSO as a control for 100% kinase activity 
(dotted line). Error bars represent the standard deviation (SD) (DMSO: dimethyl sulfoxide). 
Cell culture. The glioblastoma cell line DK-MG38 was obtained from the Leibniz Institute DSMZ (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen). Cells were grown in RPMI medium. The medium was 
supplemented with 10% fetal calf serum (FCS; Biochrom, Berlin, Germany), 100 units/ml penicillin, 100 µg/ml 
streptomycin (Gibco, Karlsruhe, Germany) and 2 mM glutamine. The cultures were kept at 37 oC in a 
humidified 5% carbon dioxide atmosphere. 
Cell viability assay. Cells were seeded at a concentration of 5 x 104 cells/ml in 96-well cell culture plates and 
allowed to attach overnight at 37 oC and 5% CO2. To investigate the effects of selected compounds on cancer 
cell proliferation, cells were treated with 10 µM of each compound, with untreated and DMSO-treated cells 
serving as a control. All media were exchanged every two days for fresh treated or control media. After an 
incubation period of 7 days at 37 oC, 10 µl of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) 12 mM solution in PBS] were added, followed by further incubation for 4 h at 37 oC. Media 
containing MTT was then removed carefully and 100 µl of 0.04 N HCl in isopropanol were added. To dissolve 
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the formazan crystals, the plates were placed for 30 min on an orbital shaker. The resulting purple solution 
was spectrophotometrically measured at 570 nm with TECAN Spectra II Plate Reader using Magellan3 (TECAN) 
as software. 
IC50 values for 2c and 4l were evaluated for their inhibition of CK1δ and CK1ε, respectively (Figure 4). 
Determination of the 50% inhibitory concentration (IC50) curves of these compounds on the kinase activities 
was performed using serial dilutions with CK1δ and CK1ε as enzymes. Kinase reactions were separated by SDS-
PAGE and the phosphate incorporation into α-casein was measured by Cherenkov counting. Obtained data 
were normalized towards their respective DMSO control reactions. Dose-response analyses were performed 
using GraphPad Prism 6, curves are shown as mean. Error bars represent the standard deviation (SD) (DMSO: 
dimethyl sulfoxide). 
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